Genentech Signs a License Agreement with Adaptimmune to Develop and Commercialize Cancer-Targeted Allogeneic T-cell Therapies
Shots:
- Adaptimmune to receive $150M up front- $150M as additional payments over 5yrs.- $3B+ as research- development- regulatory & commercial milestones along with royalties across multiple programs
- Adaptimmune can opt for 50-50 US profit/cost-share for off-the-shelf products. If it elects to opt-in- Adaptimmune will share 50% of profits & losses from US sales & receive ex-US regulatory & sales-based milestones along with royalties on ex-US net sales
- Genentech will be responsible for the input TCRs- clinical development & commercialization. Adaptimmune will lead the development of clinical candidates using its iPSC-derived allogeneic platform to produce iT cells
| Ref: Globe Newswire | Image: Adaptimmune
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
